Ganetespib: Phase II data

Data from the first stage of an open-label Phase II trial showed that ganetespib missed the pre-specified criteria of >=3 responses in 22 patients with metastatic breast cancer. Specifically,

Read the full 293 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE